S&P’s Dan Yergin warns of ‘dangerous time’ for global economy as Middle East tensions fester

S&P’s Dan Yergin warns of ‘dangerous time’ for global economy as Middle East tensions fester


Dan Yergin: Markets see the Israel-Iran conflict further escalating

The global economy is entering a “dangerous time” like never before as Middle East tensions remain elevated, said S&P Global’s vice chairman Daniel Yergin.

Since the Israel-Hamas conflict began on Oct. 7 of last year, the oil market has experienced minimal disruptions, with prices remaining under pressure as a result of increased U.S. production and weak demand from China. However, this sentiment has been shifting. Oil prices spiked last week on fears that Israel could target Iran’s oil industry in retaliation for Tehran’s ballistic missile attack, with industry analysts raising concerns about a genuine threat to supply.

“The Israelis have not concluded what they’re going to do in terms of a strike — that’s under discussion,” U.S. President Joe Biden told reporters at a White House press briefing last week, adding that he discouraged Israel from striking Iranian oil facilities.

Last week, both oil benchmarks saw their biggest weekly gain since March 2023. During Asia trading on Tuesday, global benchmark Brent slipped 1.77% to $79.50 a barrel, while U.S. West Texas Intermediate traded 1.83% lower at $75.77 per barrel.

Yergin told CNBC’s “Squawk Box Asia” that he expects Israeli retaliation will not just be a replay of last April, but something “much stronger.”

In April, Iran and Israel came to blows but ultimately avoided a full-scale war. Iran fired hundreds of ballistic missiles and drones at Israel in retaliation for an attack on an Iranian diplomatic facility in Syria.

When asked if the global economy is on the precipice of another supply shock resulting from Middle East tensions, Yergin said it’s a precarious time for markets.

“I think it’s a very dangerous time, one that we haven’t seen,” he said. 

Additionally, while Yergin maintained that it is not certain whether Iranians have operational nuclear weapons, that is still “certainly in the backdrop,” particularly through the lens of the Israelis.

“The betting is that the Israelis would not attack, try to attack, the nuclear facilities at this time. But a few months from now, a few weeks from now, whatever it is, Iran would have the capacity — it’s thought — to deliver a nuclear weapon, and that raises the stakes,” he said, likening the moment to the 1962 Cuban Missile Crisis.

That said, Israel is a lot more concerned about Iran’s nuclear facilities than the Iranian oil industry, said Pavel Molchanov, managing director of investment services firm Raymond James. Iran’s nuclear program has progressed to a stage where, in approximately one week, the country could potentially enrich enough uranium for five fission weapons, according to estimates by Iran Watch, a website published by the Wisconsin Project on Nuclear Arms Control.

“The worst-case scenario would be something that Iran can do on its own, which is a blockade of the Strait of Hormuz. So this is not directly related to Israeli airstrikes or missiles. 

The strait, between Oman and Iran, is a vital channel where about one fifth of global oil production flows daily, according to the U.S. Energy Information Administration. It is a strategically important waterway linking crude producers in the Middle East with key markets across the world.

The inability of oil to traverse through the strait, even temporarily, can increase shipping costs, lead to considerable supply delays and ratchet up global energy prices, with some surmising that a worst-case scenario could prompt oil prices to surge above $100 a barrel.



Source

Merck shells out  billion for London-based lung therapy firm Verona
World

Merck shells out $10 billion for London-based lung therapy firm Verona

Bloomberg | Bloomberg | Getty Images Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm’s respiratory treatment portfolio in a bid to diversify its revenue source beyond blockbuster cancer drug. Merck has been leaning on its aging cancer immunotherapy Keytruda, the world’s top-selling prescription medicine, […]

Read More
Singapore state investor Temasek is rethinking defense as a strategic ESG bet
World

Singapore state investor Temasek is rethinking defense as a strategic ESG bet

Defense stocks are booming — and according to one of Asia’s biggest investors, allocating capital to the sector doesn’t mean having to abandon ESG initiatives. Speaking to CNBC’s Martin Soong on Wednesday, Rohit Sipahimalani, chief investment officer at Singapore’s state investment fund Temasek, said his team were looking at opportunities in the European defense sector. […]

Read More
Shares of Ray-Ban maker EssilorLuxottica jump 6% on reported Meta stake in AI push
World

Shares of Ray-Ban maker EssilorLuxottica jump 6% on reported Meta stake in AI push

Smart Ray-Ban Glasses, on June 16, 2024, in Caen, Normandy, France. Nurphoto | Getty Images Shares of Ray-Ban maker EssilorLuxottica almost 6% on Wednesday on reports that Meta has taken a minority stake in the company amid growing appetite for AI-powered wearable devices. Meta reportedly bought a stake worth around 3 billion euros ($3.51 billion) […]

Read More